Exploration of the antibody–drug conjugate clinical landscape

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 y. In November 2022, Elahere(TM) became the latest ADC to be approved by the US Food and Drug Administration (FDA). To date, over 260 AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Maecker, Heather, Jonnalagadda, Vidya, Bhakta, Sunil, Jammalamadaka, Vasu, Junutula, Jagath R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464553/
https://www.ncbi.nlm.nih.gov/pubmed/37639687
http://dx.doi.org/10.1080/19420862.2023.2229101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464553/
https://www.ncbi.nlm.nih.gov/pubmed/37639687
http://dx.doi.org/10.1080/19420862.2023.2229101

Ejemplares similares